Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

Matinas BioPharma Inks mRNA-Based Vaccine Pact With BioNTech

BioNTech SE (NASDAQ:BNTX) and Matinas BioPharma Holdings Inc (NYSE:MTNB) have entered into an exclusive research collaboration to evaluate the combination of mRNA formats and Matinas' proprietary LNC platform technology. 

  • The companies will collaborate on formulation, optimization, and in vitro testing.
  • "We are thrilled to partner with this world-class organization to demonstrate the capabilities of our LNC platform further and potentially provide an opportunity for the oral administration of vaccines or other treatments,' said Jerome Jabbour, CEO & Co-Founder of Matinas. 
  • Related: Matinas BioPharma Stock Jumps After Meningitis Candidate Data.
  • Under the agreement terms, Matinas will receive an upfront access fee to work exclusively with BioNTech and additional research funding from BioNTech. Specific deal terms were not disclosed.
  • The parties have also commenced discussions on a license agreement for Matinas' LNC platform technology.
  • Price Action: MTNB shares are up 2.97% at $0.80, and BNTX shares are down 0.70% at $169.06 on Monday's last check.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.